食管癌中真核翻译起始因子5A2的表达及与预后的相关性  

Expression of EIF5A2 in Esophageal Squamous Cell Carcinoma and Its Correlation with the Prognosis

作　　者：陈杰伟 陈克明[1] 蔡小嘉 张新科[1] 刘君[1] 蔡木炎[1] 肖永波[1] 

机构地区：[1]华南肿瘤国家重点实验室,中山大学肿瘤防治中心病理科,广东广州510060 [2]中山大学孙逸仙纪念医院病理科,广东广州510120

出　　处：《中山大学学报（医学科学版）》2017年第4期512-516,共5页Journal of Sun Yat-Sen University:Medical Sciences

基　　金：2015中山大学青年项目(520101210104)

摘　　要：【目的】探讨真核翻译起始因子5A2(EIF5A2)在食管鳞状细胞癌(ESCC)中的表达及其临床意义。【方法】运用免疫组化方法,检测EIF5A2蛋白在135例食管鳞状细胞癌中的表达水平,分析其与临床病理参数之间的相关性及其预后价值。【结果】在135例ESCC患者中高表达68例,Pearson′s卡方检验结果显示EIF5A2在ESCC中的表达水平与T分期(P=0.006)、淋巴结转移(P=0.031)、临床分期(P=0.026)显著相关;Cox比例风险模型分析EIF5A2是ESCC患者的独立预后危险因素;Kaplan-Meier分析结果显示,低表达组患者中位生存时间72.5个月,显著高于高表达组患者的中位生存时间51.7个月(P<0.05)。【结论】EIF5A2的过表达可能促进ESCC发生与发展而且是ESCC患者预后不良的标记物。[Objective] To investigate the expression of eukaryotic translation initiation factor 5A2 （EIF5A2） and its clinical significance in esophageal squamous cell carcinoma （ESCC）. [ Methods ] Immunohistochemistry was used to detect the expression of EIF5A2 protein in 155 cases of esophageal squamous cell carcinoma, and analyzed the correlation between the expression of EIF5A2 protein and clinicopathological parameters, and its prognosis value. [Results] Immunohistochemical analysis showed that 68 cases were overexpressed in 135 cases of ESCC. Pearson＇s chi-square test indicated that the expression of EIF5A2 in ESCC was significantly correlated with T stage （P = 0.006）, lymph node metastasis （P = 0.031 ） and clinic stage （P = 0.026）. The Cox proportional hazard model analysis showed that EIF5A2 was an independent prognostic risk factor for ESCC patients. Kaplan-Meier analysis showed that the median survival time of patients with the low expression was 72.5 months, which was significantly higher than that of patients with the high expression, the median survival time of it are 51.7 months （P 〈 0.05）. [ Conclusion ] The overexpression of EIF5A2 may contribute to the development and progression of ESCC and EIF5A2 could be a novel potential prognostic marker for ESCC.

关 键 词：EIF5A2 食管鳞状细胞癌 免疫组化 预后 

分 类 号：R735.1[医药卫生—肿瘤]